After collecting blood samples from more than 32,000 women, results showed plasma levels of the sTNFR-2, not CRP or IL-6, were linked to an increased risk of CRC. Anti-inflammatory drugs seem to reduce the risk of CRC in women with high, not low, baseline levels of sTNFR-2.
Read the study about the roles of inflammatory markers and NSAIDs in CRC.
Read other coverage about colorectal cancer:
– Researchers Revisit Surveillance Colonoscopy Utilization
– 4 Steps to Increase Screening Colonoscopy Cases
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.